Peptide boom exposes evidence gaps as drug development and prescribing markets draw interest
Photo: TokenPost
Tirzepatide generated nearly $44 billion in sales in the first nine months of 2026, highlighting the commercial scale of an approved peptide medicine. Interest has spread to unapproved compounds, but their supporting evidence and market size differ sharply. In its “The State of Longevity” report published on November 3, 2026, Andreessen Horowitz said Eli Lilly recorded those sales through its Mounjaro and Zepbound brands. That puts a single FDA-approved medicine well ahead of the compounded peptide market, which the report described as worth single-digit billions of dollars.
Source: TokenPost
